| Revenue Growth | US sales $42.2M (up 3.8%); International sales declined 9% to $35M. |
|---|---|
| Mgmt Confidence | Confident in long-term opportunity but acknowledged need for urgency and discipline. |
| Demand Visibility | Softness in European capital spending expected to continue into fourth quarter. |
| Margin Trends | Adjusted gross margin 44.2%, down from 45.9% due to international mix. |
| Op. Leverage | $20M annualized savings targeted by 2027 to improve capital efficiency. |
| Vol vs Price | POC unit volume increased nearly 6%; new products added 250 bps growth. |
| Segment Growth | US growth driven by distributor demand; International lagged due to inventory management. |
| New Clients | Strategically partnering with US distributors; expanding into Asia Pacific and Latin America. |
| Capex & Debt | Divested rental business for $24.8M; $97.7M cash; zero debt; $45M buyback. |
| Commentary | Shifting focus to broader respiratory portfolio including sleep and airway clearance. |
| New Launches | Aurora and Boxy products starting to contribute to growth in adjacent markets. |
Growth
Total revenue fell 2.4% to $77.2M; US sales grew 3.8% while international sales declined 9%.
Outlook
FY2026 revenue guided to $298M-$301M with $20M annualized savings expected by end of 2027.
Risks
Management refused all live Q&A, preventing scrutiny on international capital spending softness and goodwill impairment.
The company's earnings call, NASDAQ: INGN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Inogen Inc: key numbers
- Share price
- $5.63Close, Nov 16
- Market cap
- $146M
- Shares outstanding
- 26MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Inogen Inc
All →Inogen Q3 2026 Results: Net Loss of $16.2M, Loss Widens
Inogen Inc. reported a net loss of $16.2 million for the third quarter of 2026, compared to a $5.3 million loss in the prior year, driven by a $10.6 million impairment charge. Total revenue for the quarter decreased slightly to $77.2 million, while the company's cash position declined to $81.8 million as of September 30, 2026.
- Key figure
- Net loss $16.2M
Inogen Leadership Change
Inogen appointed current COO Andy Reding as President and CEO and a member of the Board of Directors, effective October 30, 2026. He succeeds Kevin R.M. Smith, whose role as an officer and employee ended on the same date. The transition occurs as the company focuses on a more streamlined commercial model following the divestiture of its U.S. rental business.
Inogen Divestiture to Rotech Healthcare Inc. for $24.8M
Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare for an estimated $24.8 million. The divestiture is intended to streamline Inogen's commercial model and shift focus toward its product supply business, supported by a new long-term supply agreement with Rotech. Upon closing, Inogen will also increase its share repurchase authorization from $30 million to $45 million.
- Value
- $24.8M
- Counterparty
- Rotech Healthcare Inc.